Expanded hemodialysis (HDx) is an innovation that can increase the effectiveness of hemodialysis. The dialysis process is expected to promote more uremic toxins removal without causing significant hypoalbuminemia using the medium cut-off (MCO) membrane or also known as the high retention onset membrane. Compared with conventional membranes such as those of low-flux hemodialysis, high-flux hemodialysis, and hemodiafiltration, the MCO membrane in HDx is considered to be the closest to the physiology of the glomerular membrane. Several studies have shown the use of the MCO membrane in HDx provides clinical benefits and better outcome although further studies are needed to assess the long-term effect and greater impact for dialysis patients.
HumesHD, FissellWH, TiranathanagulK. The future of hemodialysis membranes. Kidney Int2006;69:1115–9.doi:10.1038/sj.ki.5000204
2.
EknoyanG, LameireN, KasiskeBL. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl2013;3:1–165.
3.
YuX. The evolving patterns of uremia: unmet clinical needs in dialysis. Contrib Nephrol2017;191:1–7.doi:10.1159/000479251http://www.ncbi.nlm.nih.gov/pubmed/28910786
4.
RoncoC. The rise of expanded hemodialysis. Blood Purif2017;44:I–VIII.doi:10.1159/000476012
5.
KirschAH, LykoR, NilssonL-G, et al. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant2017;32:165–72.doi:10.1093/ndt/gfw310http://www.ncbi.nlm.nih.gov/pubmed/27587605
6.
Boschetti-de-FierroA, VoigtM, StorrM, et al. MCO membranes: enhanced selectivity in high-flux class. Sci Rep2015;5.doi:10.1038/srep18448
7.
RoncoC, La MannaG, MannaL. Expanded hemodialysis: a new therapy for a new class of membranes. Contrib Nephrol2017;190:124–33.doi:10.1159/000468959http://www.ncbi.nlm.nih.gov/pubmed/28535525
8.
RoncoC, MarchionnaN, BrendolanA, et al. Expanded haemodialysis: from operational mechanism to clinical results. Nephrol Dial Transplant2018;33:iii41–7.doi:10.1093/ndt/gfy202
9.
MassyZA, LiabeufS. Middle-Molecule uremic toxins and outcomes in chronic kidney disease. Contrib Nephrol2017;191:8–17.doi:10.1159/000479252http://www.ncbi.nlm.nih.gov/pubmed/28910787
10.
WolleyMJ, HutchisonCA. Large uremic toxins: an unsolved problem in end-stage kidney disease. Nephrol Dial Transpl2018;33:iii6–11.doi:10.1093/ndt/gfy179
11.
KalocheretisP, RevelaI, SpanouE, et al. Strong Correlation of B 2 -Microglobulin (B 2 -m) with Procalcitonin (PCT) in the Serum of Chronic Hemodialysis Patients: A Role for Infections in the Dialysis-Related Amyloidosis?Ren Fail2008;30:261–5.doi:10.1080/08860220701857134
12.
CheungAK, RoccoMV, YanG, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HemO study. J Am Soc Nephrol2006;17:546–55.doi:10.1681/ASN.2005020132http://www.ncbi.nlm.nih.gov/pubmed/16382021
13.
SmithLK, HeY, ParkJ. β 2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. Nat Med2015:1–8.doi:10.1038/nm.3898
14.
RaoM, GuoD, PerianayagamMC, et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis2005;45:324–33.doi:10.1053/j.ajkd.2004.09.018http://www.ncbi.nlm.nih.gov/pubmed/15685511
15.
RoncoC, RoncoC. Hemodiafiltration: technical and clinical issues. Blood Purif2015;40:2–11.doi:10.1159/000437403
16.
FioreGB, RoncoC. Principles and practice of internal hemodiafiltration. Contrib Nephrol2007;158:177–84.doi:10.1159/000107248http://www.ncbi.nlm.nih.gov/pubmed/17684356
17.
RoncoC, BrendolanA, LupiA, et al. Effects of a reduced inner diameter of hollow fibers in hemodialyzers. Kidney Int2000;58:809–17.doi:10.1046/j.1523-1755.2000.00230.x
18.
LorenzinA, NeriM, ClarkWR, et al. Modeling of internal filtration in Theranova Hemodialyzers. Contrib Nephrol2017;191:127–41.doi:10.1159/000479261http://www.ncbi.nlm.nih.gov/pubmed/28910796
19.
FioreGB, GuadagniG, LupiA, et al. A new semiempirical mathematical model for prediction of internal filtration in hollow fiber hemodialyzers. Blood Purif2006;24:555–68.doi:10.1159/000097079http://www.ncbi.nlm.nih.gov/pubmed/17124424
20.
HeyneN. Expanded hemodialysis therapy: prescription and delivery. Contrib Nephrol2017;191:153–7.doi:10.1159/000479263http://www.ncbi.nlm.nih.gov/pubmed/28910798
21.
DurantonF, CohenG, De SmetR, et al. Normal and pathologic concentrations of uremic toxins. JASN2012;23:1258–70.doi:10.1681/ASN.2011121175
22.
KrishnasamyR, HawleyCM, JardineMJ, et al. A trial evaluating mid cut-off value membrane clearance of albumin and light chains in hemodialysis patients: a safety device study. Blood Purif2020;49:468–78.doi:10.1159/000505567http://www.ncbi.nlm.nih.gov/pubmed/31968346
23.
BunchA, SanchezR, NilssonL-G, et al. Medium cut-off dialyzers in a large population of hemodialysis patients in Colombia: COREXH registry. Ther Apher Dial2021;25:33–43.doi:10.1111/1744-9987.13506http://www.ncbi.nlm.nih.gov/pubmed/32352233
24.
ZicklerD, SchindlerR, WillyK, et al. Medium cut-off (MCO) membranes reduce inflammation in chronic dialysis Patients-A randomized controlled clinical trial. PLoS One2017;12:e0169024–15.doi:10.1371/journal.pone.0169024http://www.ncbi.nlm.nih.gov/pubmed/28085888
25.
CozzolinoM, MagagnoliL, CiceriP, et al. Effects of a medium cut-off (Theranova®) dialyser on haemodialysis patients: a prospective, cross-over study. Clin Kidney J2021;14:382–9.doi:10.1093/ckj/sfz155
26.
LeeY, JangM-jin, JeonJ, et al. Cardiovascular risk comparison between expanded hemodialysis using Theranova and online hemodiafiltration (Cartoon): a multicenter randomized controlled trial. Sci Rep2021;11.doi:10.1038/s41598-021-90311-6
27.
LimJ-H, ParkY, YookJ-M. Randomized controlled trial of medium cut-off versus high-flux dialyzers on quality of life outcomes in maintenance hemodialysis patients. Sci Rep2020;10:1–11.
28.
AlarconJC, BunchA, ArdilaF, et al. Impact of medium cut-off dialyzers on patient-reported outcomes: COREXH registry. Blood Purif2021;50:110–8.doi:10.1159/000508803http://www.ncbi.nlm.nih.gov/pubmed/33176299
29.
FlorensN, JuillardL. Expanded haemodialysis: news from the field. Nephrol Dial Transplant2018;33:iii48–52.doi:10.1093/ndt/gfy203
30.
MitraS, KharbandaK. Effects of expanded hemodialysis therapy on clinical outcomes. Contrib Nephrol2017;191:188–99.doi:10.1159/000479267http://www.ncbi.nlm.nih.gov/pubmed/28910802
